ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

Fungal Disease Clinical Trial

Official title: A Phase 1, Open-Label, Single-Centre Study to Evaluate the Absorption, Distribution, Metabolism and Excretion (ADME) of Oral [14^C]-Ibrexafungerp in Healthy Male Subjects After Repeat Dosing

Status Completed

Clinical Trial Summary

This is a Phase 1, open-label, single center, non-randomized study to evaluate the absorption, distribution, metabolism and excretion (ADME) of an oral solution of radiolabeled Ibrexafungerp following repeat administration in healthy male subjects. All subjects will undergo preliminary screening procedures, will remain the clinical unit for approximately 26 days and will receive radiolabeled Ibrexafungerp, orally for 3 days.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Fungal Disease
• Mycoses

• NCT number: NCT05668429
• Study type: Interventional
• Source: Scynexis, Inc.
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2022
• Completion date: January 28, 2023